Showing results (71-80 of 3,787) with videos related to

Sort By:
Pageof 379
Oncoimmunology|July 9, 2015
T cell receptor-therapy in HBV-related hepatocellularcarcinomaAntonio Bertoletti, Maurizia Brunetto, Mala K Maini, et al.
Oncoimmunology|July 9, 2015
Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapyAnna R Kwilas, Sofia R Gameiro, Peter S Kim, et al.
Oncoimmunology|February 6, 2018
Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responsesGrammatiki Fotaki, Chuan Jin, Mohanraj Ramachandran, et al.
Oncoimmunology|February 6, 2018
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiationMegan Morisada, Paul E Clavijo, Ellen Moore, et al.
Oncoimmunology|February 6, 2018
Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC studyC Mirjolet, C Charon-Barra, S Ladoire, et al.
Oncoimmunology|February 6, 2018
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environmentChiara Riganti, Marcello Francesco Lingua, Iris Chiara Salaroglio, et al.
Oncoimmunology|February 6, 2018
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell linesSunil S Raikar, Lauren C Fleischer, Robert Moot, et al.
Oncoimmunology|February 6, 2018
Melanoma induced immunosuppression is mediated by hematopoietic dysregulationNeha Kamran, Youping Li, Maria Sierra, et al.
Oncoimmunology|January 9, 2018
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacyCatherine A Sabatos-Peyton, James Nevin, Ansgar Brock, et al.
Oncoimmunology|January 9, 2018
Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancerMei Zhang, Liane Chun, Victor Sandoval, et al.
Pageof 379